IQVIA Holdings Inc (IQV)vsNeoGenomics Inc (NEO)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
NEO
NeoGenomics Inc
$7.77
-1.15%
HEALTHCARE · Cap: $1.01B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 2142% more annual revenue ($16.31B vs $727.33M). IQV leads profitability with a 8.3% profit margin vs -14.8%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
NEO
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Intrinsic value data unavailable for NEO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Reasonable price relative to book value
Earnings expanding 130.6% YoY
Areas to Watch
Distress zone — elevated risk
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -12.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : NEO
The strongest argument for NEO centers on Price/Book, EPS Growth. Revenue growth of 10.6% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
IQV profiles as a value stock while NEO is a turnaround play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.64 — expect wider price swings.
NEO is growing revenue faster at 10.6% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (72/100 vs 51/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?